Clinical trial

Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

NCT06937476

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Escitalopram Normalized identity: escitalopramView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Aripiprazole 5mg Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2025-05-08

PhaseNA

Conditions

Major Depressive Disorder (MDD)unresolved

Ruminationverified · MONDO: rumination disorder

Interventions

EscitalopramDRUG · verified · RxNorm: escitalopram

Aripiprazole 5mgDRUG

Sponsors & collaborators

Central South Universitylead sponsor

Second Xiangya Hospital of Central South Universitycollaborator

National Natural Science Foundation of Chinacollaborator

Mapped research locations

ChangshaHunan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06937476 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.